

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

ETAS ID: TM433462

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Cardiome Pharma Corp.		06/20/2017	Corporation: CANADA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	CRG Servicing LLC		
<b>Street Address:</b>	1000 Main Street		
<b>Internal Address:</b>	Suite 2500		
<b>City:</b>	Houston		
<b>State/Country:</b>	TEXAS		
<b>Postal Code:</b>	77002		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86971229	CARDIOME	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2127352000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	212.735.5117		
<b>Email:</b>	francine.waldbaum@skadden.com		
<b>Correspondent Name:</b>	Skadden, Arps, Slate, Meagher & Flom LLP		
<b>Address Line 1:</b>	Four Times Square		
<b>Address Line 2:</b>	Francine Waldbaum		
<b>Address Line 4:</b>	New York, NEW YORK 10036		
<b>ATTORNEY DOCKET NUMBER:</b>	122920/6		
<b>NAME OF SUBMITTER:</b>	Matthew B. Zisk		
<b>SIGNATURE:</b>	/Matthew B. Zisk/		
<b>DATE SIGNED:</b>	06/30/2017		
<b>Total Attachments: 7</b>			
source=Canadian Patent and Trademark Security Agreement#page1.tif			
source=Canadian Patent and Trademark Security Agreement#page2.tif			
source=Canadian Patent and Trademark Security Agreement#page3.tif			

CH \$40.00 86971229

source=Canadian Patent and Trademark Security Agreement#page4.tif  
source=Canadian Patent and Trademark Security Agreement#page5.tif  
source=Canadian Patent and Trademark Security Agreement#page6.tif  
source=Canadian Patent and Trademark Security Agreement#page7.tif

## PATENT AND TRADEMARK SECURITY AGREEMENT

WHEREAS, CARDIOME PHARMA CORP. (“**Grantor**”), is party to that certain Canadian Security Agreement, dated as of June 13, 2016 (as amended, restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), among Grantor, the Subsidiary Guarantors party thereto and CRG SERVICING LLC, as administrative and collateral agent (in such capacity, together with its successors and assigns, the “**Administrative and Collateral Agent**”), pursuant to which Grantor has granted in favor of Secured Parties a lien on all of its personal property, including without limitation the patents and patent applications listed on **Schedule A** hereto, and the trademarks and trademark applications listed on the **Schedule B** hereto; and

WHEREAS, it is a condition to the advance of the loans and other obligations secured by the Security Agreement, that Grantor execute and deliver, and cause to be filed in the Canadian Intellectual Property Office, the United States Patent and Trademark Office and any other applicable intellectual property office in another jurisdiction, this Patent and Trademark Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

As collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise) of its Secured Obligations, Grantor hereby pledges and grants to the Administrative and Collateral Agent for the benefit of the Secured Parties a security interest in all of Grantor’s right, title and interest in, to and under all of the following, as collateral security for the prompt and complete payment and performance when due of all the Secured Obligations (as defined in the Security Agreement):

(i) all patents, patent applications, industrial designs and industrial design applications in each case whether now owned by Grantor or hereafter acquired and whether now existing or hereafter coming into existence, including without limitation those listed on **Schedule A** hereto, and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith; and

(ii) all of the trademarks, whether now owned or at any time hereafter acquired, of Grantor that are registered with, or for which applications for registration have been filed with, the Canadian Intellectual Property Office, the United States Patent and Trademark Office, or other applicable intellectual property office in another jurisdiction, including the trademarks listed on **Schedule B** hereto, and all registrations and pending applications associated therewith (excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application).

Notwithstanding the foregoing, in the event of any conflict between this Patent and Trademark Security Agreement and the Security Agreement, the Security Agreement shall control.

This Patent and Trademark Security Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the Province of British Columbia and the federal laws of Canada applicable therein.

[signature to follow]

IN WITNESS WHEREOF, Grantor has caused this Patent and Trademark Security Agreement to be duly executed and delivered as of 20, June, 2017.

**CARDIOME PHARMA CORP., as Grantor**

By   
Name: Jennifer Archibald  
Title: Chief Business Operations Officer  
Date: 20 June 20, 2017

By   
Name: David D. McMasters  
Title: General Counsel  
Date: 20 June 20, 2017

Schedule A  
to Patent and Trademark Security Agreement

PATENTS AND PATENT APPLICATIONS

United States

Name	File Ref No.	Country	Title	Appl. No.	Appl. Date	Patent No.	Patent Date
BRINAVESS	480102.403C15	United States	ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF	15/383,933	12/19/2016		
BRINAVESS	480102.420D3	United States	SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS	15/416,952	01/26/2017		

# Other Jurisdictions

Name	File Ref No.	Country	Title	Appl. No.	Appl. Date	Patent No.	Patent Date
BRINAVESS	480102.403EP	Europe	AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF	99911550.4	04/01/1999	1087934	02/25/2004
BRINAVESS	480102.411EP	Europe	AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF	3781611.3	10/31/2003	1560812	05/10/2006
BRINAVESS	480102.411EP D1	Europe	AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF	6000750.7	10/31/2003	1666459	10/19/2011
BRINAVESS	480102.439MX <sup>2</sup>	Mexico	SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS	MX/a/2014/009461	06/15/2006		
BRINAVESS	CARD.402FR	France	PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS	11818552.9	08/08/2011	2605772	09/22/2016
BRINAVESS	CARD.402DE	Germany	PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS	11818552.9	08/08/2011	2605772	09/22/2016
BRINAVESS	CARD.402NL	Netherlands	PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS	11818552.9	08/08/2011	2605772	09/22/2016
BRINAVESS	CARD.402CH	Switzerland	PROCESS FOR PREPARING	11818552.9	08/08/2011	2605772	09/22/2016

Name	File Ref No.	Country	Title	Appl. No.	Appl. Date	Patent No.	Patent Date
			AMINOCYCLOHEXYL ETHER COMPOUNDS				
BRINAVESS	CARD.402GB	United Kingdom	PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS	11818552.9	08/08/2011	2605772	09/22/2016
BRINAVESS	CRDI- 013/00EP	Europe	A NEW DOSING REGIMEN FOR ION CHANNEL MODULATING COMPOUNDS FOR TREATING ACUTE ATRIAL FIBRILLATION IN A HUMAN	5826333.6	11/08/2005	1868598	04/23/2014

**Schedule B  
to Patent and Trademark Security Agreement**

**TRADEMARKS AND TRADEMARK APPLICATIONS**

United States

Trademark	File Ref. No.	Country	Appl. No.	Filing Date	Reg No.	Reg date
CARDIOME	480102-276	United States of America	86/971229	04-11-2016		

Other Jurisdictions

Trademark	File Ref. No.	Country	Appl. No.	Filing Date	Reg No.	Reg date
AGRASTAT		Argentina	3555398	10-28-2016		
AGRASTAT		Nicaragua	2016-004222	10-28-2016		
AGGRASTAT		United Arab Emirates	265753	12-30-2016		
AGRASTAT		Venezuela	2272-17	02-13-2017		
BRINAVESS		Argentina	3555398	10-18-2016		